Why did the Imugene (ASX:IMU) share price hit a new all-time high today?

The Imugene Limited share price hit an all-time high today, but with no news from the company since Tuesday, some market watchers are wondering why.

The Imugene Limited (ASX: IMU) share price hit an all-time high of 41 cents in intraday trade today, but with no news from the company since Tuesday, some market watchers are wondering why.

At the time of writing, the Imugene share price has retreated slightly, however, are still up 6.85%. Shares in the immuno-oncology company are swapping hands for 39 cents apiece.

The last time we heard from Imugene, it announced it had entered into a global patient license for a novel cancer therapy.

The following day (AEST), Imugene shared to its website that United States-based investment banking firm ROTH Capital Partners had given its shares a 12-month price target of 42 cents.  

Since then, the Imugene share price has gained 16.67%

Let's take a closer look at the news that's seemingly driving shares in Imugene.

three excited doctors with hands in the air

Image source: Getty Images

Imugene's good news day

On Tuesday, Imugene announced it had entered into an agreement with City of Hope, an independent cancer research and treatment centre, to license the patient for its CD19 therapy.

The technology under the license is an extension of chimeric antigen receptor (CAR) T cell cancer therapy. Currently, CAR T cell therapy can only be used to treat blood or liquid-based cancers. City of Hope's technology has the potential to treat solid cancers.

Imugene's first clinical trial of CD19 is planned to begin in 2022.

As a result of the news, ROTH Capital upgraded its guidance for Imugene shares to 42 cents yesterday.

ROTH Capital's price target was based on a number of factors, including the projected future revenue of Imugene's CHECKvacc, HER-Vaxx, and PD1-Vaxx.

The banking firm expects these products will bring in a combined $1.7 billion in royalties by the 2031 financial year.

Imugene share price snapshot

On Tuesday, the day Imugene's latest news broke, the company's share price finished flat with its previous close.

Then, after ROTH Capital's analysis yesterday it shot up to close 10.61% higher. It's gained another 6.8% today.

The company's share price gains this week add to what has been a fantastic performance on the ASX recently.

Currently, the Imugene share price is 285% higher than it was at the start of 2021. It's also gained 1,183% since this time last year when its shares were trading for 3 cents.

The company has a market capitalisation of around $1.7 billion, with approximately 4.7 billion shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »